Results 61 to 70 of about 3,256,982 (294)

Where to go to in chlamydia control? From infection control towards infectious disease control

Sexually Transmitted Infections, 2021
Objectives The clinical and public health relevance of widespread case finding by testing for asymptomatic chlamydia infections is under debate. We wanted to explore future directions for chlamydia control and generate insights that might guide for ...
J. van Bergen, B. Hoenderboom, Silke David, F. Deug, J. Heijne, F. van Aar, C. Hoebe, H. Bos, N. Dukers-Muijrers, H. Götz, N. Low, S. Morré, B. Herrmann, M. V. D. van der Sande, H. D. de Vries, H. Ward, B. V. van Benthem   +16 more
semanticscholar   +1 more source

Branching model with state dependent offspring distribution for Chlamydia spread [PDF]

arXiv, 2023
Chlamydiae are bacteria with an interesting unusual developmental cycle. A single bacterium in its infectious form (elementary body, EB) enters the host cell, where it converts into its dividing form (reticulate body, RB), and divides by binary fission.
arxiv  

Microbial risk factors of cardiovascular and cerebrovascular diseases: potential therapeutic options [PDF]

, 2008
Infection and inflammation may have a crucial role in the pathogenesis of atherosclerosis. This hypothesis is supported by an increasing number of reports on the interaction between chronic infection, inflammation, and atherogenesis.
Abbas, M.A., Comi, G, Corea, F, Fawi, G, Galantucci, S, Guenther, A, Kwan, Joseph W.   +6 more
core   +1 more source

Prevalence of HIV, HBV and Chlamydia infections in Cameroonian University context: case of the University of Dschang, in the Western Region [PDF]

, 2015
Introduction: In sub-Saharan Africa HIV infection remains largely epidemic, whereas HBV infection is highly endemic (>8%). In Cameroon, HIV prevalence is 4.3%. Concerning HBV and chlamydia infections, their prevalence are both ≥10%.
Colizzi, V., Djeunang Dongho, G. B., Donfack, J. H., Fokam, J., Mbongue, G., Mpoame, M., Nkamedjie, P. P. M., Onohiol, J. F., Russo, G., Sanou Sobze, M., Watcho, P.   +10 more
core  

A 2-pyridone-amide inhibitor targets the glucose metabolism pathway of Chlamydia trachomatis. [PDF]

, 2014
UnlabelledIn a screen for compounds that inhibit infectivity of the obligate intracellular pathogen Chlamydia trachomatis, we identified the 2-pyridone amide KSK120.
Almqvist, Fredrik, Bastidas, Robert J, Bergström, Sven, Chorell, Erik, Engström, Patrik, Hultgren, Scott J, Krishnan, K Syam, Ngyuen, Bidong D, Normark, Johan, Silver, Jim, Valdivia, Raphael H, Welch, Matthew D, Wolf-Watz, Hans   +12 more
core   +4 more sources

Engineered Tissue Models to Decode Host–Microbiota Interactions

Advanced Science, EarlyView.
Host–Microbiota interactions in the human body. Created in BioRender. Ghezzi, C. (2025) https://BioRender.com/ihivskg. Abstract A mutualistic co‐evolution exists between the host and its associated microbiota in the human body. Bacteria establish ecological niches in various tissues of the body, locally influencing their physiology and functions, but ...
Miryam Adelfio, Grace E. Callen, Xuesong He, Bruce J. Paster, Hatice Hasturk, Chiara E. Ghezzi   +5 more
wiley   +1 more source

Chlamydia trachomatis and the risk of spontaneous preterm birth, babies who are born small for gestational age, and stillbirth: A population-based cohort study [PDF]

, 2018
Background: Chlamydia trachomatis is one of the most commonly diagnosed sexually transmitted infections worldwide, but reports in the medical literature of an association between genital chlamydia infection and adverse obstetric outcomes are inconsistent.
Donovan, Basil, Hocking, Jane S, Liu, Bette, Mak, Donna B, Preen, David, Reekie, Joanne, Roberts, Christine, Ward, James   +7 more
core   +1 more source

Developing and testing accelerated partner therapy for partner notification for people with genital Chlamydia trachomatis diagnosed in primary care: a pilot randomised controlled trial [PDF]

, 2015
Background Accelerated partner therapy (APT) is a promising partner notification (PN) intervention in specialist sexual health clinic attenders. To address its applicability in primary care, we undertook a pilot randomised controlled trial (RCT) of two
Althaus, Andrew Copas, Anne M Johnson, Bailey, Cassell, Catherine H Mercer, Centers for Disease Control and Prevention, Chen, Claudia S Estcourt, Cowan, Estcourt, Estcourt, Ferreira, Greta Rait, Götz, Jackie A Cassell, Kazeem Aderogba, Laura Tickle, Lorna J Sutcliffe, Louise J Jackson, Low, Low, McCarney, McNulty, McNulty, McNulty, Mercer, Mercer, Mercer, Merle Symonds, Miller, Pamela Muniina, Roberts, Sarah Creighton, Shackleton, Tracy E Roberts, Turner   +36 more
core   +6 more sources

Influence of the tryptophan-indole-IFNγ axis on human genital Chlamydia trachomatis infection: role of vaginal co-infections

Frontiers in Cellular and Infection Microbiology, 2014
The natural history of genital Chlamydia trachomatis infections can vary widely; infections can spontaneously resolve but can also last from months to years, potentially progressing to cause significant pathology.
Ashok A. Aiyar, A. Quayle, Lyndsey R. Buckner, S. Sherchand, Theresa L. Chang, A. Zea, D. Martin, R. Belland   +7 more
semanticscholar   +1 more source

Human Cervix Chip: A Preclinical Model for Studying the Role of the Cervical Mucosa and Microbiome in Female Reproductive Health

BioEssays, EarlyView.
The microfluidic Cervix Chip is an in vitro model of the human cervix lined by cervical epithelium interfaced with stromal cells cultured under dynamic flow that represents a new preclinical platform for studying mucosal immunity, host‐microbiome interactions, infections, fertility, and pregnancy health.
Zohreh Izadifar, Anna Stejskalova, Aakanksha Gulati, Ola Gutzeit, Donald E. Ingber   +4 more
wiley   +1 more source